首页> 美国卫生研究院文献>other >Cervical cancer treatment with a locally insertable controlled release delivery system
【2h】

Cervical cancer treatment with a locally insertable controlled release delivery system

机译:用局部可插入的控释递送系统治疗宫颈癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Local delivery of cancer chemotherapeutics enables sustained drug levels at the site of action thereby reducing systemic side effects. A novel insertable polymeric drug delivery system for cervical cancer treatment is presented. Cisplatin, the first line of therapy employed for cervical cancers, was incorporated in a poly(ethylene-co-vinyl acetate) (EVAc) device that is similar to those currently used for vaginal contraceptive delivery. Cisplatin crystals were uniformly dispersed in the polymeric system without undergoing significant dissolution in the polymer matrix. Cisplatin dissolution from the devices was biphasic, consistent with a matrix-type controlled-release system with an initial rapid release phase followed by a slower, linear release phase. Depending on the drug loading in the polymeric devices, the near-linear release phase varied in rate according both empirical, linear curve-fitting (0.38±0.15 μg/day to 46.9±10.0 μg/day) and diffusion analysis based upon diffusion through a porous structure (Dapp from 1.3±0.5×10−9 cm2/s to 5.8±0.3×10−12 cm2/s). The devices were tested for in vitro activity and found to be effective against both HPV positive and HPV negative cervical cancer cell lines. Preliminary studies indicate that this delivery system would be a good candidate for investigation as a choice of treatment in cervical cancers.
机译:癌症化学治疗剂的局部递送使作用部位的药物水平持续升高,从而降低了全身性副作用。提出了一种用于宫颈癌治疗的新型可插入聚合物药物递送系统。顺铂是治疗宫颈癌的第一线疗法,已被并入类似于目前用于阴道避孕药的聚乙烯(乙烯-乙酸乙烯酯)(EVAc)装置。顺铂晶体均匀地分散在聚合物体系中,而没有明显溶解在聚合物基质中。从装置中顺铂的溶出是双相的,与基质型控释系统相一致,该系统具有最初的快速释放阶段,随后是缓慢的线性释放阶段。根据聚合物装置中的药物负载,近线性释放相的速率根据经验,线性曲线拟合(0.38±0.15μg/天至46.9±10.0μg/天)和基于通过扩散的扩散分析而变化。多孔结构(Dapp从1.3±0.5×10 −9 cm 2 / s到5.8±0.3×10 −12 cm 2 / s)。测试了该设备的体外活性,发现它们对HPV阳性和HPV阴性宫颈癌细胞系均有效。初步研究表明,该输送系统将是宫颈癌治疗的理想选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号